Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Metsera is a clinical‐stage biotech firm developing oral & injectable hormone therapies to treat obesity & related metabolic diseases.
Alpha-9 Oncology is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies.
Aktis Oncology is a biotechnology company that designs and develops novel class radiopharmaceuticals.
Ventyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders.
Inspirato is a luxury travel and lifestyle subscription company.
Day One Biopharmaceuticals develops targeted therapies to treat people with life-threatening diseases.
Scorpion Therapeutics is a clinical-stage oncology company that specializes in precision medicine for cancer patients.
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Mereo is a new UK-based speciality biopharmaceutical company.
CARGO Therapeutics develops an adoptive cell therapy to benefit patients from potentially curative treatment options.
P3 Health Partners is a patient-centered, physician-led and population health-focused healthcare company.
ITeos Therapeutics is a biotechnology company that specializes in tumor immunology, cancer immunotherapy, and drug discovery.
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.
Nkarta Therapeutics is a developer of cell engineering platform created to build the next generation of cell therapies.
Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
Applied Therapeutics uses drug-development approach to target molecules and pathways that has roles in fatal or debilitating diseases.
Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients.
Parse Biosciences is a biotechnology startup company that develops single-cell sequencing kit solutions for researchers.
Verve Therapeutics is a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease.
QuantumScape develops solid-state lithium-metal batteries for electric vehicles and other energy storage applications.
Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.
TwinStrand Biosciences develops and commercializes the duplex sequencing technology for DNA sequencing.
Black Diamond Therapeutics is a medical company focused on analyzing genetically defined cancers.
Janus Henderson Investors has invested in 229 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Janus Henderson Investors's top investment sectors include Biotechnology, Health Care, Medical, Life Science, Therapeutics. The firm invests across 30 different industry categories.
Among tracked funding rounds, Akero Therapeutics received $366.9M in a Post-IPO Equity round. Janus Henderson Investors's total known invested capital is $34.7B.
Janus Henderson Investors's average investment size is $151.4M across its portfolio of 229 companies.
Recent Janus Henderson Investors portfolio additions include Metsera, Alpha-9 Oncology, Aktis Oncology, Ventyx Biosciences, Inspirato. These companies were founded in 2020 or later.